Board Change • May 21
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Executive Director of Strategy & Strategic Partnerships and Executive Director Andrew Garth is the most experienced director on the board, commencing their role in 2024. Independent Non- Executive Director Andrew Bottrell was the last independent director to join the board, commencing their role in 2026. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Tillkännagivande • Oct 14
Aurora Labs Limited has completed a Follow-on Equity Offering in the amount of AUD 5.5 million. Aurora Labs Limited has completed a Follow-on Equity Offering in the amount of AUD 5.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 59,602,251
Price\Range: AUD 0.052
Discount Per Security: AUD 0.00312
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 46,166,980
Price\Range: AUD 0.052
Discount Per Security: AUD 0.00312
Transaction Features: Subsequent Direct Listing Tillkännagivande • Oct 09
Aurora Labs Limited, Annual General Meeting, Nov 17, 2025 Aurora Labs Limited, Annual General Meeting, Nov 17, 2025. New Risk • Nov 17
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Revenue is less than US$1m (AU$174k revenue, or US$112k). Minor Risk Market cap is less than US$100m (€18.3m market cap, or US$19.3m). Tillkännagivande • Nov 06
Aurora Labs Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million. Aurora Labs Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 26,666,667
Price\Range: AUD 0.075
Discount Per Security: AUD 0.00375
Transaction Features: Subsequent Direct Listing Tillkännagivande • Sep 24
Aurora Labs Limited, Annual General Meeting, Nov 14, 2024 Aurora Labs Limited, Annual General Meeting, Nov 14, 2024. Reported Earnings • Aug 23
Full year 2024 earnings released: AU$0.01 loss per share (vs AU$0.014 loss in FY 2023) Full year 2024 results: AU$0.01 loss per share (improved from AU$0.014 loss in FY 2023). Net loss: AU$2.81m (loss narrowed 5.3% from FY 2023). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Tillkännagivande • May 01
Aurora Labs Limited, Annual General Meeting, May 30, 2024 Aurora Labs Limited, Annual General Meeting, May 30, 2024, at 10:00 W. Australia Standard Time. Location: 41-43 Wittenberg Drive, Canning Vale, Western Australia Canning Vale Western Australia Australia Agenda: To consider the Ratification of Placement Shares pursuant to Listing Rule 7.1; to consider the Issue of Placement Options; to consider the Issue of Placement Shares and Placement Options to Mr Grant Mooney; and to consider other matters. Tillkännagivande • Apr 23
Aurora Labs Limited has filed a Follow-on Equity Offering in the amount of AUD 2.04 million. Aurora Labs Limited has filed a Follow-on Equity Offering in the amount of AUD 2.04 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 65,166,667
Price\Range: AUD 0.03
Discount Per Security: AUD 0.0018
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,833,333
Price\Range: AUD 0.03
Discount Per Security: AUD 0.0018
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing New Risk • Feb 25
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.6m free cash flow). Share price has been highly volatile over the past 3 months (38% average weekly change). Revenue is less than US$1m (AU$220k revenue, or US$144k). Market cap is less than US$10m (€4.92m market cap, or US$5.32m). Minor Risk Shareholders have been diluted in the past year (26% increase in shares outstanding). Tillkännagivande • Dec 22
Aurora Labs Limited ORDINARY FULLY PAID to Be Deleted from OTC Equity Aurora Labs Limited ORDINARY FULLY PAID (Australia) will be deleted from OTC Equity effective December 21, 2023, due to Inactive Security. Tillkännagivande • Nov 29
Aurora Labs Limited has completed a Follow-on Equity Offering in the amount of AUD 0.9416 million. Aurora Labs Limited has completed a Follow-on Equity Offering in the amount of AUD 0.9416 million.
Security Name: Ortdinary Shares
Security Type: Common Stock
Securities Offered: 35,800,000
Price\Range: AUD 0.022
Security Name: Ortdinary Shares
Security Type: Common Stock
Securities Offered: 7,000,000
Price\Range: AUD 0.022
Transaction Features: Subsequent Direct Listing New Risk • Nov 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.6m free cash flow). Share price has been highly volatile over the past 3 months (47% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (AU$135k revenue, or US$89k). Market cap is less than US$10m (€4.43m market cap, or US$4.87m). New Risk • Nov 28
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.6m free cash flow). Share price has been highly volatile over the past 3 months (46% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (AU$135k revenue, or US$89k). Market cap is less than US$10m (€3.90m market cap, or US$4.28m). Tillkännagivande • Oct 27
Aurora Labs Limited, Annual General Meeting, Nov 29, 2023 Aurora Labs Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: HLB Mann Judd, Level 4, 130 Stirling Street Perth, Western Australia Western Australia Australia Agenda: To consider the Annual Report of the Company and its controlled entities for the year ended 30 June 2023, which includes the Financial Report, the Directors' Report and the Auditor's Report; to consider remuneration report; to consider re-election of director; and to consider other matters. Reported Earnings • Aug 27
Full year 2023 earnings released: EPS: AU$0.014 (vs AU$0.018 loss in FY 2022) Full year 2023 results: EPS: AU$0.014 (up from AU$0.018 loss in FY 2022). Net loss: AU$2.96m (loss narrowed 5.9% from FY 2022). Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Board Change • Apr 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Non-Executive Chairman & Company Secretary Grant Mooney was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 24
First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.011 loss in 1H 2022) First half 2023 results: AU$0.009 loss per share (improved from AU$0.011 loss in 1H 2022). Net loss: AU$1.69m (loss narrowed 4.9% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 26
Full year 2022 earnings released: AU$0.018 loss per share (vs AU$0.031 loss in FY 2021) Full year 2022 results: AU$0.018 loss per share (up from AU$0.031 loss in FY 2021). Net loss: AU$3.15m (loss narrowed 29% from FY 2021). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Apr 15
Founder & CTO recently sold €211k worth of stock On the 14th of April, David Budge sold around 3m shares on-market at roughly €0.074 per share. This was the largest sale by an insider in the last 3 months. David has been a seller over the last 12 months, reducing personal holdings by €372k. Reported Earnings • Aug 28
Full year 2021 earnings released: AU$0.03 loss per share (vs AU$0.079 loss in FY 2020) Full year 2021 results: Net loss: AU$4.42m (loss narrowed 46% from FY 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Aug 03
Founder & CTO recently sold €140k worth of stock On the 29th of July, David Budge sold around 2m shares on-market at roughly €0.057 per share. This was the largest sale by an insider in the last 3 months. David has been a seller over the last 12 months, reducing personal holdings by €649k. 
